CAW
RVNC

Cornerstone Advisors (Washington)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2K Buy
74
+20
+37% +$524 ﹤0.01% 613
2020
Q2 		$1K Hold
54
– – ﹤0.01% 695
2020
Q1 		$1K Hold
54
– – ﹤0.01% 733
2019
Q4 		$1K Buy
+54
New +$837 ﹤0.01% 738

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Cornerstone Advisors (Washington)'s RVNC Position: Q3 2020 in Review

Cornerstone Advisors (Washington) increased its Revance Therapeutics, Inc. (RVNC) stake by 37% in Q3 2020, buying an estimated $524 and bringing the position to 74 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #613.

Cornerstone Advisors (Washington) first reported a position in RVNC in Q4 2019 and has held it in 4 quarters since. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

  • Cornerstone Advisors (Washington) held 74 shares of Revance Therapeutics, Inc. worth $2K as of Q3 2020.
  • Cornerstone Advisors (Washington) bought 20 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $524.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #613 holding.
  • Cornerstone Advisors (Washington) first reported a position in Revance Therapeutics, Inc. in Q4 2019 and has held it in 4 quarters since.
  • 153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.